BCM
ANIK icon

BlueCrest Capital Management’s Anika Therapeutics ANIK Stock Holding History

BlueCrest Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,896
Closed -$516K – 820
2017
Q3 		$516K Buy
+8,896
New +$465K 0.02% 511

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

BlueCrest Capital Management's ANIK Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Anika Therapeutics (ANIK) in Q4 2017, closing a stake of 8,896 shares — an estimated $516K sold.

BlueCrest Capital Management first reported a position in ANIK in Q3 2017 and held it in 1 quarter. The position peaked at $516K in Q3 2017. 172 funds tracked by Wall St. Rank hold ANIK as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Anika Therapeutics position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 8,896 Anika Therapeutics shares in Q4 2017, an estimated $516K.
  • BlueCrest Capital Management first reported a position in Anika Therapeutics in Q3 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Anika Therapeutics position peaked at $516K in Q3 2017.
  • 172 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.